[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"entinostat\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:entinostat":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100613054",false,"NCT07261592","Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer","Entinostat Combined With Chemotherapy as Second-line Therapy for Unresectable Locally Advanced or Metastatic Bladder Cancer: A Single-arm, Prospective Clinical Trial","Inclusion Criteria:\n\n* Histopathologic confirmed unresectable advanced or metastatic bladder cancer, except for those with squamous differentiation, glandular differentiation or both;\n* Failure of first-line treatment;\n* There is at least one measurable lesion according to RECIST 1.1;\n* Archived tumor tissue samples or tumor biopsies must be provided;\n* ECOG score of 0-1 an an estimated survival of at least 6 months;\n* Adequate organ function;\n* Patients voluntarily participated in this study, signed the informed consent form, and had good compliance;\n* Women with fertility must consent to contraception during the study and for 6 months after the last dose of study drug.\n\nExclusion Criteria:\n\n* Patients who received platinum-based chemotherapy after failure of first-line treatment;\n* Patients who received platinum-based chemotherapy withnin a 24 month before this trial;\n* Those who have received other anti-tumor treatment or participated in other clinical studies within 4 weeks before the start of the study, or have not recovered from the last toxicity (except grade 2 hair loss and grade 1 neurotoxicity);\n* Concomitant disease such as uncontrolled hypertension or diabetes, renal inadequacy, myocardial infarction, severe angina;\n* Female subjects who are pregnant, breastfeeding or planning to become pregnant during the study;\n* Patients with serious physical or mental illnesses.","ALL","18 Years","75 Years",{"count":19,"type":20},29,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This single-center single-arm, open-label prospective clinical trial aimed to evaluate the efficacy and safety of entinostat combined with chemotherapy as second-line therapy for unresectable locally advanced or metastatic bladder cancer.",[27,28,29,30],"Bladder Cancer","Histone Deacetylase Inhibitor","Entinostat","Chemotherapy","NOT_YET_RECRUITING","2025-11-22",{"date":34,"type":35},"2025-12-03","ACTUAL",{"date":37,"type":20},"2025-12-01",{"date":39,"type":20},"2029-04-30",{"name":41,"class":42},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",""]